<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-id journal-id-type="publisher-id">wox</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization Journal</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3512726</article-id><article-id pub-id-type="doi">10.1097/01.WOX.0000411961.02158.51</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts of the XXII World Allergy Congress</subject></subj-group><subj-group subj-group-type="heading"><subject>Poster Symposium</subject></subj-group><series-title>Immunotherapy</series-title></article-categories><title-group><article-title>204 IGE/IGG4 Ratio as a Possible Surrogate Marker of Clinical Efficacy During Allergen-Specific Immunotherapy with House Dust Mite Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Labrada</surname><given-names>Alexis</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mateo</surname><given-names>Maytee</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Naranjo</surname><given-names>Rosa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Allergens, National Center of Bioproducts, Mayabeque, Cuba</aff><aff id="aff2"><label>2</label>Alllergy, “Joaquin Albarran” Hospital, Havana, Cuba.</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><volume>5</volume><issue>Suppl 2</issue><issue-title>Abstracts of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, México</issue-title><fpage seq="c">S84</fpage><lpage>S84</lpage><permissions><copyright-statement>Copyright © 2012 by World Allergy Organization</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="waoj-5-S84b.pdf"></self-uri><abstract><sec><title><offsets xml_i="2550" xml_f="2560" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="2571" xml_f="2976" txt_i="22" txt_f="427">Allergen immunotherapy (AIT) induces IgG4 antibodies with blocking effect, and long-term reduction of IgE. The problem of finding suitable surrogate paraclinical markers during AIT is currently very relevant. The aim was to evaluate the allergen-specific IgE/IgG4 ratio as an immunological correlate to clinical efficacy during AIT with House Dust Mite (HDM) allergen vaccines in Cuban asthmatic patients.</offsets></p></sec><sec><title><offsets xml_i="2998" xml_f="3005" txt_i="429" txt_f="436">Methods</offsets></title><p><offsets xml_i="3016" xml_f="3167" txt_i="437" txt_f="588">Three separate Double-Blind Placebo-Controlled clinical trials of AIT were performed using standardized registered allergen extracts of 3 HDM species: </offsets><italic><offsets xml_i="3175" xml_f="3205" txt_i="588" txt_f="618">Dermatophagoides pteronyssinus</offsets></italic><offsets xml_i="3214" xml_f="3241" txt_i="618" txt_f="645">, and the tropical species </offsets><italic><offsets xml_i="3249" xml_f="3259" txt_i="645" txt_f="655">D. siboney</offsets></italic><offsets xml_i="3268" xml_f="3273" txt_i="655" txt_f="660"> and </offsets><italic><offsets xml_i="3281" xml_f="3298" txt_i="660" txt_f="677">Blomia tropicalis</offsets></italic><offsets xml_i="3307" xml_f="3682" txt_i="677" txt_f="1052">. Each clinical trial included 40 asthmatic patients, totalling 120 individuals. Half of them received placebo. Allergen-specific IgE and IgG4 antibodies were measured by ELISA. Antibody titres were normalized and averaged between the 3 trials. Size effect was calculated as the Standard Mean Difference (SMD) between the active and placebo groups, using meta-analysis tools.</offsets></p></sec><sec><title><offsets xml_i="3704" xml_f="3711" txt_i="1054" txt_f="1061">Results</offsets></title><p><offsets xml_i="3722" xml_f="3775" txt_i="1062" txt_f="1115">There was a significant increase of IgG4 antibodies (</offsets><italic><offsets xml_i="3783" xml_f="3784" txt_i="1115" txt_f="1116">P</offsets></italic><offsets xml_i="3793" xml_f="3932" txt_i="1116" txt_f="1252"> &lt; 0.05) after 6 months of treatment. At 12 months, the IgG4 increase was even greater and the IgE decrease achieved also significance (</offsets><italic><offsets xml_i="3940" xml_f="3941" txt_i="1252" txt_f="1253">P</offsets></italic><offsets xml_i="3950" xml_f="4674" txt_i="1253" txt_f="1974"> &lt; 0.05). Thus, IgG4 induction appeared to precede IgE changes, in agreement with the possible role of the Treg/IL-10 response induction at the initial AIT phase. Moreover, 83% of patients showed a decrease of the IgE/IgG4 ratio in the active groups, whereas only 32% showed reduction in placebo groups. The IgE/IgG4 ratio was the immunological variable with the greatest size effect value (SMD = 0.81 95% CI, 0.71-0.91), as compared to changes in IgE or IgG4 levels, alone. The size effect value was close to the clinical effect (symptom-medication score SMD = 1.2 95% CI, 0.7-1.7). Per-patient changes in IgG4 levels, as well as, in the IgE/IgG4 ratio, were significantly correlated to the symptom-medication variable (</offsets><italic><offsets xml_i="4682" xml_f="4683" txt_i="1974" txt_f="1975">r</offsets></italic><offsets xml_i="4692" xml_f="4701" txt_i="1975" txt_f="1984"> = 0.23, </offsets><italic><offsets xml_i="4709" xml_f="4710" txt_i="1984" txt_f="1985">P</offsets></italic><offsets xml_i="4719" xml_f="4728" txt_i="1985" txt_f="1994"> = 0.04).</offsets></p></sec><sec><title><offsets xml_i="4750" xml_f="4761" txt_i="1996" txt_f="2007">Conclusions</offsets></title><p><offsets xml_i="4772" xml_f="5030" txt_i="2008" txt_f="2266">These results support the use of the IgE/IgG4 ratio as an easily measurable marker for monitoring the allergen-specific immunity during AIT with HDM in asthmatic patients, and possibly, for predicting patient's clinical improvement after 1 year of treatment.</offsets></p></sec></abstract></article-meta></front></article>